INNOVATION
THAT GOES
BEYOND
HEALING

ABOUT US

Life After Well

At Qcil, we believe that health isn't merely the absence of illness, but the vibrant pursuit of life's possibilities. In Africa, vitality and resilience are virtues we celebrate – which is why for us, it's not about surviving, it's about thriving. This is what makes us more than just medication manufacturers. We embody the spirit of living vigorously – at the heart of our commitment to scientific innovation and true wellness, captured in our mantra, "Life After Well”.

home right 1
Human Care - Uganda
vision

Vision

To become a center of excellence in the manufacturing of quality affordable and newer medicines.

mission

Mission

To provide affordable and efficacious medicines in a sustainable way, in order to improve the quality of life.

standards

Standards

Qcil's plant has been designed to meet the world’s most stringent regulatory standards.

culture

Governance

In September 2018, following a successful Initial Public Offering, Qcil shares were listed on the Uganda Securities Exchange.

values

Values

Quality Excellence Accountability Teamwork Integrity Customer Focus Innovation

WHO ARE WE

Made in Africa, for Africa

At Qcil we are dedicated to producing high-quality, affordable, life-saving medicines because we believe Africans deserve to live long and healthy lives. We envision a future where good health is the norm for all, not just a privileged few. This is why we are committed to ensuring that no one is denied access to essential medications. Our mission extends beyond medicine, we are committed to making a meaningful difference.

home right 2

Growth Opportunities

Qcil is committed to producing high-quality, affordable medicines that is easily accessible to meet the growing demands of Africa's increasing population. Beyond treating malaria, HIV, and Hepatitis B, Qcil is also pioneering innovative treatments that will manage the surge of non-communicable diseases (NCDs) and cancer. Following a successful Initial Public Offering in September 2018, Qcil shares were listed on the Uganda Securities Exchange for the first time.

Corporate Culture

Qcil employs over 350 permanent staff, with 38% being female. As an equal opportunity employer, we do not discriminate based on gender, age, disability, ethnicity, religion, or nationality. We take great pride in the quality of our employees by giving them access to development opportunities, training and empowering them to be innovative and enhancing their ability to deliver the best results for both our business and Africans.

Our Leadership

Board of Directors

Emmanuel Katongol

Emmanuel Katongol

Board Chairman & Co-founder
View Biography
Frederick Kitaka Mutebi

Frederick Kitaka Mutebi

Co-Founder & Director
View Biography
George Baguma

George Baguma

Co-Founder & Director
View Biography
Ajay Kumar Pal

Ajay Kumar Pal

Chief Executive Officer
View Biography
Beth Lisa Mandel

Beth Lisa Mandel

Non-Executive Director
View Biography
Joseph Baliddawa

Joseph Baliddawa

Independent Non-Executive Director
View Biography
Professor Peter Mugyenyi

Professor Peter Mugyenyi

Independent Non-Executive Director
View Biography
Stevens Mwanje

Stevens Mwanje

Non-Executive Director
View Biography
Vusi Raseroka

Vusi Raseroka

Non-Executive Director
View Biography

Management Team

Ajay Kumar Pal

Ajay Kumar Pal

Chief Executive Officer
View Biography
Fred Kakooza

Fred Kakooza

Chief Finance Officer
View Biography
Atul Vadepalli

Atul Vadepalli

Quality Assurance Manager
View Biography
Kikundwa Emma Mbabazi

Kikundwa Emma Mbabazi

Company Pharmacist
View Biography
Harrison Kiggundu

Harrison Kiggundu

Human Resource Manager
View Biography
Peace Namara

Peace Namara

Acting Company Secretary
View Biography
Ramakanta Panda

Ramakanta Panda

Head of Operations
View Biography
Sarah S. Musumba

Sarah S. Musumba

ESG Lead
View Biography
Mahdev Mandhare

Mahdev Mandhare

Head of Supply Chain
View Biography

MILESTONES & AWARDS

award icon copy

WINNER

National Environment Sustainability Award for Exceptional Management of Active Chemicals (NEMA 2024)

award icon copy

WINNER

Federation Of Uganda Employer Award For Disability Inclusion 2023

award icon copy

WINNER

Outstanding Performance In Occupational Safety & Health Management For The Year 2023

award icon copy

WINNER

Best Practices In Learning And Development - 2022 Survey

award icon copy

WINNER

Employer Of The Year Award - 2021/22 Survey

award icon copy

WINNER

Best Reward And Recognition Award - Prudential Best HR Practice Survey 2021

award icon copy

WINNER

Financial Reporting Award - Fire Awards 2021

award icon copy

WINNER

Indian Business Forum Award (Contribution Towards The Pharmaceutical/Health Sector: 2018)

award icon copy

WINNER

Africa Award For Entrepreneurship (Transformational Business Of The Year: 2012)

award icon copy

WINNER

Outstanding Achievement In Development Of The Pharmaceutical Sector (Ministry Of Health: 2012)

award icon copy

WINNER

Investor Of The Year (Uganda Investment Authority: 2007)

MANUFACTURING
EXCELLENCE

WHO-compliant Facilities

Qcil aims to produce pharmaceutical products of the highest quality, that adhere strictly to cGMP and GLP, and numerous other international regulatory standards.

Qcil is one of the largest pharmaceutical manufacturers in East Africa and also one of the largest in SSA. Qcil is one of the few pharmaceutical manufacturers to operate a WHO cGMP-compliant facility, which manufactures a range of WHO pre-qualified medicines for treating HIV/AIDS and malaria.

about manufatoring excellence
iso

ISO Certified

Qcil has obtained ISO certifications for Environmental Management Systems (SO 14001:2015) and Occupational Health and Safety Management Systems (ISO 45001:2018). This helps Qcil promote better environmental management systems. We take pride in holding ourselves account

Factory Tour

Qcil has focused on aggressive market expansion over the past few years. As a result, the company has obtained approval from national regulatory bodies across numerous African countries. Qcil is listed for approval in South Africa, the single biggest market for antiretrovirals in the world.The facility is approved for supply in 31 SSA countries and currently exports to 13 countries in Africa and 2 in South East Asia. Qcil's manufacturing facility has also been expanded, increasing production capacity from 80 million to 130 million tablets monthly, to meet demand.

In December 2019, Qcil commissioned a
$10- million state-of-the-art quality control laboratory, which is double the size of the previous laboratory, accommodating more staff, and ensuring that the company is compliant with all safety and good laboratory practice requirements.The new facility has also helped to increase productivity and improve production timelines.

The new facility has also helped to increase productivity and improve production timelines.

Qcil constructed a new $5 million warehouse, with 3000 sqm, to increase in-house storage capacity and discontinue the use of third-party warehouses. The warehouse has been operational since January 2019 and has capacity for 5000 pallets.

Cipla Uganda Factory Tour: A journey of 60 million doses